Common blood thinner can be repurposed as an inexpensive antidote for cobra venom

FHS
July 18, 2024
12:34 pm

Scientists at the University of Sydney and Liverpool School of Tropical Medicine have made a remarkable discovery: a commonly used blood thinner, heparin, can be repurposed as an inexpensive antidote for cobra venom.

Why are Genentech cancer researchers worried?

This story first appeared in The Readout newsletter. Sign up for The Readout and receive STAT’s award-winning biotech news delivered straight to your inbox. A busy end of this

September 27, 2024

New FDA rule for pharma advertisements requires side effects to be explained clearly

Ever notice how the narrator of a drug advertisement on TV can breeze through the side effects in a tone that’s easy to tune out?

November 21, 2023

Tattoos could be a risk factor for lymphoma, study suggests

A new study from Lund University in Sweden suggests that tattoos could be a risk factor for cancer in the lymphatic system, or lymphoma.

May 24, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.